Hyperkalemia treatment trends in the ED are varied and inconsistent, depending on potassium levels when patients reach the ED. Although various treatments decreased potassium over 4 hours, only ...

A recent population-based study assessed the incidence of clinically significant hyperkalemia among adult CKD patients being treated with RAASis and how this affected future treatment. In the study, 9 ...

WILMINGTON, Del.--(BUSINESS WIRE)--Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA ® (sodium zirconium cyclosilicate) to include a dosing ...

The FDA and Relypsa announced that the agency has approved patiromer, a potassium-binding agent, for the treatment of patients with hyperkalemia. Perspective from Javed Butler, MD, MPH Patiromer ...

Postoperative hyperkalemia is an important complication of adrenalectomy for aldosterone-producing adenoma. Recently, postoperative hyperkalemia has been found to have a relatively high incidence ...

It can be administered orally or in an enema. ANI Pharmaceuticals announced the launch of Kionex ® (sodium polystyrene sulfonate suspension USP) for Oral or Rectal Use for the treatment of ...

In a European study, approximately one-third of hospitalizations involving patients with recurrent hyperkalemia directly related to serum potassium elevation. Recurrent hyperkalemia is a major cause ...

Objectives: This study examined renin-angiotensin-aldosterone system (RAAS) inhibitor dose levels in a US patient population and investigated the impact of hyperkalemia on RAAS inhibitor dose and the ...

Prescription pills Mineralocorticoid receptor antagonist treatment is often not recommended in patients with advanced kidney disease due to perceived risk of hyperkalemia and death, investigators ...

ST. GALLEN, Switzerland, Sept. 24, 2024 /PRNewswire/ -- CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd.